Joseph M. Burnett serves as Chief Executive Officer of ClearPoint Neuro, Inc., a leading medical device company specializing in precision neuro-navigation platforms for drug delivery, biologics, and gene therapy procedures targeting the brain and spine. With more than 25 years of executive experience in the medical technology sector, Burnett brings a proven track record of driving commercial growth, operational excellence, and strategic innovation. His career has spanned finance, operations, and general management roles at high-growth medtech firms. Prior to joining ClearPoint Neuro, Burnett was President and CEO of ReShape Lifesciences Inc., where he led transformative initiatives in obesity treatment devices and therapies. At Nevro Corp., a neuromodulation leader, he advanced from Chief Financial Officer to Chief Operating Officer, overseeing rapid revenue expansion from $50 million to over $350 million annually, international market entries, and key acquisitions. Earlier positions included Vice President of Finance at ev3 Inc. (acquired by Covidien) and various finance leadership roles at Guidant Corporation, building his expertise in corporate development, investor relations, and scaling businesses. Appointed CEO of ClearPoint Neuro in February 2023, Burnett has accelerated the company's commercialization efforts, forged strategic partnerships with biotech leaders, and expanded its SmartFrame Orbital platform adoption in minimally invasive neurosurgery. Under his guidance, ClearPoint Neuro has achieved record procedural volumes, strengthened its biologics and gene therapy pipeline, and positioned the company for sustained growth in the burgeoning field of precision neurotherapeutics.